240 related articles for article (PubMed ID: 23396449)
1. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.
Kandimalla ER; Bhagat L; Wang D; Yu D; Sullivan T; La Monica N; Agrawal S
Nucleic Acids Res; 2013 Apr; 41(6):3947-61. PubMed ID: 23396449
[TBL] [Abstract][Full Text] [Related]
2. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.
Wang D; Bhagat L; Yu D; Zhu FG; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2009 Jan; 52(2):551-8. PubMed ID: 19102653
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
[TBL] [Abstract][Full Text] [Related]
5. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice.
Zhu FG; Jiang W; Bhagat L; Wang D; Yu D; Tang JX; Kandimalla ER; La Monica N; Agrawal S
Autoimmunity; 2013 Nov; 46(7):419-28. PubMed ID: 24083389
[TBL] [Abstract][Full Text] [Related]
6. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis.
Jiang W; Zhu FG; Bhagat L; Yu D; Tang JX; Kandimalla ER; La Monica N; Agrawal S
J Invest Dermatol; 2013 Jul; 133(7):1777-84. PubMed ID: 23370539
[TBL] [Abstract][Full Text] [Related]
7. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9.
Wang J; Shao Y; Bennett TA; Shankar RA; Wightman PD; Reddy LG
J Biol Chem; 2006 Dec; 281(49):37427-34. PubMed ID: 17040905
[TBL] [Abstract][Full Text] [Related]
8. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
9. Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity.
Vlach J; Bender AT; Przetak M; Pereira A; Deshpande A; Johnson TL; Reissig S; Tzvetkov E; Musil D; Morse NT; Haselmayer P; Zimmerli SC; Okitsu SL; Walsky RL; Sherer B
J Pharmacol Exp Ther; 2021 Mar; 376(3):397-409. PubMed ID: 33328334
[TBL] [Abstract][Full Text] [Related]
10. TLR7 and TLR8 Differentially Activate the IRF and NF-κB Pathways in Specific Cell Types to Promote Inflammation.
Bender AT; Tzvetkov E; Pereira A; Wu Y; Kasar S; Przetak MM; Vlach J; Niewold TB; Jensen MA; Okitsu SL
Immunohorizons; 2020 Feb; 4(2):93-107. PubMed ID: 32086319
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines.
Marron TU; Martinez-Gallo M; Yu JE; Cunningham-Rundles C
J Allergy Clin Immunol; 2012 Jan; 129(1):184-90.e1-4. PubMed ID: 22088613
[TBL] [Abstract][Full Text] [Related]
12. Dual or triple activation of TLR7, TLR8, and/or TLR9 by single-stranded oligoribonucleotides.
Forsbach A; Samulowitz U; Völp K; Hofmann HP; Noll B; Tluk S; Schmitz C; Wader T; Müller C; Podszuweit A; Lohner A; Curdt R; Uhlmann E; Vollmer J
Nucleic Acid Ther; 2011 Dec; 21(6):423-36. PubMed ID: 22196370
[TBL] [Abstract][Full Text] [Related]
13. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.
Lan T; Kandimalla ER; Yu D; Bhagat L; Li Y; Wang D; Zhu F; Tang JX; Putta MR; Cong Y; Trombino AF; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13750-5. PubMed ID: 17698957
[TBL] [Abstract][Full Text] [Related]
14. Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8.
Lan T; Bhagat L; Wang D; Dai M; Kandimalla ER; Agrawal S
Bioorg Med Chem Lett; 2009 Apr; 19(7):2044-7. PubMed ID: 19269175
[TBL] [Abstract][Full Text] [Related]
15. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells.
Römmler F; Hammel M; Waldhuber A; Müller T; Jurk M; Uhlmann E; Wagner H; Vollmer J; Miethke T
PLoS One; 2015; 10(2):e0116703. PubMed ID: 25695778
[TBL] [Abstract][Full Text] [Related]
16. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo.
Lamphier M; Zheng W; Latz E; Spyvee M; Hansen H; Rose J; Genest M; Yang H; Shaffer C; Zhao Y; Shen Y; Liu C; Liu D; Mempel TR; Rowbottom C; Chow J; Twine NC; Yu M; Gusovsky F; Ishizaka ST
Mol Pharmacol; 2014 Mar; 85(3):429-40. PubMed ID: 24342772
[TBL] [Abstract][Full Text] [Related]
17. IFN-γ stimulates CpG-induced IL-10 production in B cells via p38 and JNK signalling pathways.
Imbrechts M; De Samblancx K; Fierens K; Brisse E; Vandenhaute J; Mitera T; Libert C; Smets I; Goris A; Wouters C; Matthys P
Eur J Immunol; 2018 Sep; 48(9):1506-1521. PubMed ID: 30004580
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9.
Guiducci C; Tripodo C; Gong M; Sangaletti S; Colombo MP; Coffman RL; Barrat FJ
J Exp Med; 2010 Dec; 207(13):2931-42. PubMed ID: 21115693
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.
Tan Y; Watkins AA; Freeman BB; Meyers JA; Rifkin IR; Lerner A
J Immunol; 2015 Jan; 194(1):101-12. PubMed ID: 25416804
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
Wang D; Precopio M; Lan T; Yu D; Tang JX; Kandimalla ER; Agrawal S
Mol Cancer Ther; 2010 Jun; 9(6):1788-97. PubMed ID: 20515950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
